Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wyrażenie świadomej zgody na udział w badaniu.
- •Potwierdzony laboratoryjnie rak żołądka lub połączenia przełykowo-żołądkowego, który jest zaawansowany i nie można go usunąć operacyjnie lub daje przerzuty.
- •Brak wcześniejszego leczenia systemowego dla zaawansowanego raka żołądka lub połączenia przełykowo-żołądkowego.
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu.
- •Wiek co najmniej 18 lat.
- •Wymagany jest pomiar przynajmniej jednej zmiany nowotworowej.
- •Odpowiednia czynność narządów wewnętrznych potwierdzona badaniami laboratoryjnymi.
- •Przewidywana długość życia co najmniej 3 miesiące.
✗ Disqualifies
- •Potwierdzenie innego typu nowotworu niż rak gruczołowy.
- •Obecność dodatniego HER2 (w badaniach IHC lub ISH/FISH).
- •Aktywne choroby ośrodkowego układu nerwowego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (25)
Mayo Clinic
Phoenix, United States
UCLA Health
Los Angeles, United States
Rocky Mountain Cancer Centers
Denver, United States
Yale School of Medicine
New Haven, United States
Dana Farber Cancer Institute
Boston, United States
Henry Ford Health
Detroit, United States
Mount Sinai
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Oregon Health and Science University
Portland, United States
Sarah Cannon Research Institute (SCRI) - Oncology Partners
Nashville, United States
Baylor Scott & White Health
Dallas, United States
MD Anderson Cancer Center
Houston, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Peking University Cancer Hospital, Gastrointestinal Cancer Center I
Beijing, China
Peking University Cancer Hospital, Gastrointestinal Oncology
Beijing, China
Guangdong Provincial People's Hospital
Guangzhou, China
Zhongshan Hospital Fudan University
Shanghai, China
Universitaetsklinikum Essen
Essen, Germany
University Cancer Center Frankfurt
Frankfurt, Germany
Universitätsmedizin der Johannes Gutenberg-Universität
Mainz, Germany
Univerity Marburg
Marburg, Germany
Pratia MCM Kraków
Krakow, Poland
Pratia Poznań
Poznan, Poland
Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie
Warsaw, Poland
Trial contact
Zhifang Yao, MD
Yelena Janjigian, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.